Overall, our custom sequencing panel targeting commonly mutated genes in melanoma was effective in providing mutational information in most patients, allowing for identification of targetable mutations for ctDNA analyses in patients WT for BRAF and NRAS. This evidence concerns the gene NRAS and melanoma.